Biopharma: Clinical Trial Pipeline Tracker

Research evidence excerpt

Biopharma: Clinical Trial Pipeline Tracker

Update

May 22, 2026 10:24 AM GMT

Morgan Stanley & Co. LLCMBiopharma | North America Terence C Flynn, Ph.D.

Equity Analyst

Clinical Trial Pipeline Tracker Terence.Flynn@morganstanley.comSean Laaman, Ph.D. +1 212 761-2230

Sean.Laaman@morganstanley.com +1 212 761-4947

We highlight key changes to the clinical trials of companies Michael E Ulz

under coverage occurring from 5/13-5/20. See inside for a full list EquityMike.Ulz@morganstanley.comAnalyst +1 212 761-4650

of changes. Judah C. Frommer, CFA

Judah.Frommer@morganstanley.com +1 212 761-1270

Maxwell SkorMNew Trials ( Exhibit 1 ) Equity Analyst

Maxwell.Skor@morganstanley.com +1 212 761-4804

• Argenx: The company has initiated a Ph2 trial (NCT07583641) to Learn Chris Yu, J.D., Ph.D.

About How Well the Medicine Efgartigimod Works to Treat Autoimmune Equity Analyst

Chris.L.Yu@morganstanley.com +1 212 761-2535

Encephalitis In Children 12 Years or Older and Adults Alexander Yevdokimov, Ph.D.

• Argenx: The company has initiated a Ph3 trial (NCT07596849) to Assess Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With

Connor M Massari

Graves' Disease Equity Analyst

• Eli Lilly: The company has initiated a Ph2 trial (NCT07589595) of Connor.Massari@morganstanley.com +1 212 761-2417

Michael H Riad, Ph.D.

Donanemab (LY3002813) in Participants With Early Cognitive Decline Research Associate

(TRAILBLAZER-ALZ 7) Michael.Riad@morganstanley.com +1 212 761-1309

Katherine Sun

• Eli Lilly: The company has initiated a Ph2 trial (NCT07589608) to Evaluate Research Associate

the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Katherine.Sun@morganstanley.com +1 212 761-5968